Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kenkre

Showing results (211-220 of 288) with videos related to

Pageof 29
Sort By:
Annals of Clinical Biochemistry|January 10, 2025
Standardising lipid testing and reporting in the United Kingdom; a joint statement by HEART UK and The Association for Laboratory MedicineJulia S Kenkre, Tina Mazaheri, R Dermot G Neely, et al.
European Journal of Endocrinology|September 1, 2017
Roles of increased glycaemic variability, GLP-1 and glucagon in hypoglycaemia after Roux-en-Y gastric bypassGeorge Tharakan, Preeshila Behary, Nicolai J Wewer Albrechtsen, et al.
Leukemia & Lymphoma|December 15, 2010
T-cell-depleted allogeneic transplant without donor leukocyte infusions results in excellent long-term survival in patients with multiply relapsed Lymphoma. Predictors for survival after transplant relapseVaishalee P Kenkre, Sarah Horowitz, Andrew S Artz, et al.
Kidney Medicine|July 3, 2025
Patient Perceptions of a Population Health Management Program to Improve Kidney Care: Optimizing care in CKDLinda-Marie U Lavenburg, Susan M Devaraj, Ambreen Gul, et al.
Leukemia & Lymphoma|August 26, 2011
Maintenance rituximab following induction chemo-immunotherapy for mantle cell lymphoma: long-term follow-up of a pilot study from the Wisconsin Oncology NetworkVaishalee P Kenkre, Walter L Long, Jens C Eickhoff, et al.
The Lancet. Oncology|July 14, 2022
Zandelisib with continuous or intermittent dosing as monotherapy or in combination with rituximab in patients with relapsed or refractory B-cell malignancy: a multicentre, first-in-patient, dose-escalation and dose-expansion, phase 1b trialJohn M Pagel, Jacob D Soumerai, Nishitha Reddy, et al.
Circulation. Cardiovascular Quality and Outcomes|December 9, 2017
Ten-Year Mortality in the WISE Study (Women's Ischemia Syndrome Evaluation)Tanya S Kenkre, Pankaj Malhotra, B Delia Johnson, et al.
Gut|April 1, 1990
Dyspepsia in England and ScotlandR H Jones, S E Lydeard, F D Hobbs, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|October 17, 2017
Fludarabine and Busulfan versus Fludarabine, Cyclophosphamide, and Rituximab as Reduced-Intensity Conditioning for Allogeneic Transplantation in Follicular LymphomaNarendranath Epperla, Kwang Woo Ahn, Philippe Armand, et al.
Toxicology and Applied Pharmacology|January 26, 2024
Nonclinical pharmacokinetics, pharmacodynamics and safety assessment of a FLT3L-Fc molecule for cancer immunotherapyKai Connie Wu, Adeyemi O Adedeji, Tanja S Zabka, et al.
Pageof 29

Showing results (211-220 of 288) with videos related to

Sort By:
Pageof 29
Annals of Clinical Biochemistry|January 10, 2025
Standardising lipid testing and reporting in the United Kingdom; a joint statement by HEART UK and The Association for Laboratory MedicineJulia S Kenkre, Tina Mazaheri, R Dermot G Neely, et al.
European Journal of Endocrinology|September 1, 2017
Roles of increased glycaemic variability, GLP-1 and glucagon in hypoglycaemia after Roux-en-Y gastric bypassGeorge Tharakan, Preeshila Behary, Nicolai J Wewer Albrechtsen, et al.
Leukemia & Lymphoma|December 15, 2010
T-cell-depleted allogeneic transplant without donor leukocyte infusions results in excellent long-term survival in patients with multiply relapsed Lymphoma. Predictors for survival after transplant relapseVaishalee P Kenkre, Sarah Horowitz, Andrew S Artz, et al.
Kidney Medicine|July 3, 2025
Patient Perceptions of a Population Health Management Program to Improve Kidney Care: Optimizing care in CKDLinda-Marie U Lavenburg, Susan M Devaraj, Ambreen Gul, et al.
Leukemia & Lymphoma|August 26, 2011
Maintenance rituximab following induction chemo-immunotherapy for mantle cell lymphoma: long-term follow-up of a pilot study from the Wisconsin Oncology NetworkVaishalee P Kenkre, Walter L Long, Jens C Eickhoff, et al.
The Lancet. Oncology|July 14, 2022
Zandelisib with continuous or intermittent dosing as monotherapy or in combination with rituximab in patients with relapsed or refractory B-cell malignancy: a multicentre, first-in-patient, dose-escalation and dose-expansion, phase 1b trialJohn M Pagel, Jacob D Soumerai, Nishitha Reddy, et al.
Circulation. Cardiovascular Quality and Outcomes|December 9, 2017
Ten-Year Mortality in the WISE Study (Women's Ischemia Syndrome Evaluation)Tanya S Kenkre, Pankaj Malhotra, B Delia Johnson, et al.
Gut|April 1, 1990
Dyspepsia in England and ScotlandR H Jones, S E Lydeard, F D Hobbs, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|October 17, 2017
Fludarabine and Busulfan versus Fludarabine, Cyclophosphamide, and Rituximab as Reduced-Intensity Conditioning for Allogeneic Transplantation in Follicular LymphomaNarendranath Epperla, Kwang Woo Ahn, Philippe Armand, et al.
Toxicology and Applied Pharmacology|January 26, 2024
Nonclinical pharmacokinetics, pharmacodynamics and safety assessment of a FLT3L-Fc molecule for cancer immunotherapyKai Connie Wu, Adeyemi O Adedeji, Tanja S Zabka, et al.
Pageof 29